BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn.

BCRXW

Contact:

John Bluth





EN
10/02/2025

Underlying

BCRXBioCryst Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Announces Departure of Dr. Helen Thackray

BioCryst Announces Departure of Dr. Helen Thackray RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year. Dr. Thackray first joined the company as a member of the board of directors in 2019 and was appointed chief research and development officer in 2021. She was a finalist internal candidate considered by the board of directors in the chief executive officer succession process....

August 11, 2025 1 EN
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
RARE ULTRAGENYX PHARMACEUTICAL INC.
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NTLA INTELLIA THERAPEUTICS INC.
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
INC
08/08/25 August 8, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 89,750 shares, of BioCryst common stock. The options and RSUs were granted as of August 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in...

August 6, 2025 1 EN
Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
MELI MERCADOLIBRE INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ARDX ARDELYX INC
TSEM TOWER SEMICONDUCTOR LTD
PLTR PALANTIR TECHNOLOGIES
PAY PAYMENTUS HLDGS INC
TMC THE METALS COMPANY INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
08/05/25 August 5, 2025 1 EN
Laura Chico
  • Laura Chico
BCRX BIOCRYST PHARMACEUTICALS INC.
08/04/25 August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch